CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
PharmaShijiazhuang, Hebei, China · Est. 1997
CSPC Zhongqi Pharmaceutical Technology Co., Ltd. is a Chinese pharmaceutical company focused on the development and commercialization of innovative drugs and traditional Chinese medicines.
13
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
22
Indications↗
Distinct diseases across all programs
165
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
13 drugs in development
Approved1
Phase 36
Phase 28
Phase 13
By Therapeutic Area
top 5
Oncology
739%
Respiratory
211%
Rare Disease
16%
Infectious Disease
16%
Immunology
16%
R&D Momentum
69/100
Pipeline Velocity
39/100
Trial Completion Rate
68/100
Pipeline Concentration
28/100
Pipeline Freshness
51/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 31, 2026
Completed
Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Double-Dummy, Placebo-controlled and Sertraline Active-controlled, Parallel-group, Phase III Study
Oct 24, 2026
Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of SYH2082 Injection in Healthy Participants
Earlier
Sep 12, 2026TrialA Randomized, Parallel-group, Multicenter Phase II Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Long-acting Octreotide Injection in Patients With Acromegaly.
Sep 5, 2026TrialA Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
Sep 2, 2026TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Preliminarily Evaluate the Efficacy and Safety of SYH2085 Tablets in Chinese Adult Participants With Uncomplicated Influenza
Aug 13, 2026TrialA Phase I Study to Evaluate BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020 Injection) in Patients With Refractory Generalized Myasthenia Gravis
Aug 12, 2026TrialEvaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.
Jul 11, 2026TrialA Single-Center, Non-Randomized, Open-Label, Parallel-Group Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Multiple Doses of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
3 more events
Jul 11, 2026TrialA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Liver Function
Jul 10, 2026TrialAn Open-Label, Multi-Center Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2095 in Advanced Malignant Tumors
Jul 7, 2026TrialA Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
Details
Company Info
Therapeutic Focus
OncologyCardiovascularAntibiotics
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology(1 drug)
—
1
—
—
—
Immunology(1 drug)
Infectious Disease(1 drug)
—
—
1
—
—
Infectious Disease(1 drug)
Oncology(7 drugs)
—
1
5
3
—
Oncology(7 drugs)
Rare Disease(1 drug)
—
—
—
—
1
Rare Disease(1 drug)
Respiratory(2 drugs)
—
—
1
1
—
Respiratory(2 drugs)
Unknown / Other(6 drugs)
—
2
1
3
—
Unknown / Other(6 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)